ECSP14010249A - Compuestos beta-lactámicos sustituidos con amidina, su preparación y uso como agentes antimicrobianos - Google Patents

Compuestos beta-lactámicos sustituidos con amidina, su preparación y uso como agentes antimicrobianos

Info

Publication number
ECSP14010249A
ECSP14010249A ECIEPI201410249A ECPI201410249A ECSP14010249A EC SP14010249 A ECSP14010249 A EC SP14010249A EC IEPI201410249 A ECIEPI201410249 A EC IEPI201410249A EC PI201410249 A ECPI201410249 A EC PI201410249A EC SP14010249 A ECSP14010249 A EC SP14010249A
Authority
EC
Ecuador
Prior art keywords
preparation
lactam compounds
antimicrobial agents
substituted beta
amidine substituted
Prior art date
Application number
ECIEPI201410249A
Other languages
English (en)
Spanish (es)
Inventor
Guofeng Jia
Guido Schiffer
Heike Broetz-Oesterhelt
Judy Yip
Ou Ligong
Chuanjun Gao
Sabiha Tajammul
Samarendra N Maiti
Mostafa Hena
Jehangir Khan
Andhe Reddy
Irith Wiegand
Zhixiang Yang
Burkhard Klenke
Rahim Mohammad
Ganguli Biswajeet
Hong Liang
Original Assignee
Aicuris Gmbh Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh Co Kg filed Critical Aicuris Gmbh Co Kg
Publication of ECSP14010249A publication Critical patent/ECSP14010249A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ECIEPI201410249A 2012-01-24 2014-07-22 Compuestos beta-lactámicos sustituidos con amidina, su preparación y uso como agentes antimicrobianos ECSP14010249A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24

Publications (1)

Publication Number Publication Date
ECSP14010249A true ECSP14010249A (es) 2015-12-31

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201410249A ECSP14010249A (es) 2012-01-24 2014-07-22 Compuestos beta-lactámicos sustituidos con amidina, su preparación y uso como agentes antimicrobianos

Country Status (42)

Country Link
US (2) US9556165B2 (enExample)
EP (1) EP2806873B1 (enExample)
JP (1) JP5869701B2 (enExample)
KR (1) KR102036393B1 (enExample)
CN (1) CN104203237A (enExample)
AP (1) AP2014007880A0 (enExample)
AR (1) AR089796A1 (enExample)
AU (1) AU2013211575B2 (enExample)
BR (1) BR112014017968A8 (enExample)
CA (1) CA2862338C (enExample)
CL (1) CL2014001956A1 (enExample)
CO (1) CO7101240A2 (enExample)
CU (1) CU24273B1 (enExample)
CY (1) CY1117955T1 (enExample)
DK (1) DK2806873T3 (enExample)
EA (1) EA027126B1 (enExample)
EC (1) ECSP14010249A (enExample)
ES (1) ES2592403T3 (enExample)
HR (1) HRP20161171T1 (enExample)
HU (1) HUE030452T2 (enExample)
IL (1) IL233805A (enExample)
IN (1) IN2014MN01640A (enExample)
LT (1) LT2806873T (enExample)
MA (1) MA35905B1 (enExample)
ME (1) ME02532B (enExample)
MX (1) MX346602B (enExample)
MY (1) MY173843A (enExample)
NZ (1) NZ626951A (enExample)
PE (1) PE20142345A1 (enExample)
PH (1) PH12014501671B1 (enExample)
PL (1) PL2806873T3 (enExample)
PT (1) PT2806873T (enExample)
RS (1) RS55210B1 (enExample)
SG (1) SG11201403930XA (enExample)
SI (1) SI2806873T1 (enExample)
SM (1) SMT201600354B (enExample)
TN (1) TN2014000297A1 (enExample)
TW (1) TWI659953B (enExample)
UA (1) UA110880C2 (enExample)
UY (1) UY34585A (enExample)
WO (1) WO2013110643A1 (enExample)
ZA (1) ZA201405057B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160326157A1 (en) * 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
PT3122745T (pt) 2014-03-24 2019-04-30 Novartis Ag Compostos orgânicos de monobactama para o tratamento de infeções bacterianas
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
PT3353175T (pt) * 2015-09-23 2020-09-10 Novartis Ag Sais e formas sólidas de um antibiótico monobactâmico
CN108368040B (zh) 2015-12-15 2024-08-23 默沙东有限责任公司 二芳基单环β-内酰胺化合物及其用于治疗细菌感染的方法
EP3426248B1 (en) * 2016-03-07 2023-11-15 Merck Sharp & Dohme LLC Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
IL264686B2 (en) 2016-08-26 2024-07-01 Codexis Inc Engineered imine reductases and methods for reversible amination of ketone and amine compounds
CA3043976A1 (en) 2016-11-18 2018-05-24 Aicuris Gmbh & Co. Kg Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections
AU2017361875A1 (en) 2016-11-18 2019-06-06 Aicuris Gmbh & Co. Kg Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
EP3558987A1 (en) * 2016-12-21 2019-10-30 AiCuris GmbH & Co. KG COMBINATION THERAPY WITH AMIDINE SUBSTITUTED ß-LACTAM COMPOUNDS AND ß-LACTAMASE INHIBITORS FOR INFECTIONS WITH ANTIBIOTIC RESISTANT BACTERIAL STRAINS
US20200181117A1 (en) 2017-07-18 2020-06-11 Bayer Cropscience Aktiengesellschaft Substituted 3-heteroaryloxy-1h-pyrazoles and salts thereof and their use as herbicidal active substances
WO2019020810A1 (en) 2017-07-28 2019-01-31 Aicuris Anti-Infective Cures Gmbh CRYSTALLINE FORM OF (2S) -2 - [[(Z) - [- 1- (2-AMINO-4-THIAZOLYL) -2 - [[(3S) -2,2-DIMETHYL-4-OXO] -Acid 1- (SULFOOXY) -3-AZETIDINYL] AMINO] -2-OXOETHYLIDENE] AMINO] OXY] -3- [4- [IMINO [(3R) -3-PIPERIDINYLAMINO] METHYL] PHENOXY] -PROPANOIC
ES2912656T3 (es) 2017-08-02 2022-05-26 Novartis Ag Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico
CN118496221A (zh) 2017-10-02 2024-08-16 默沙东有限责任公司 用于治疗细菌感染的苯并二氢吡喃单环β-内酰胺类化合物
EP3676247B8 (en) * 2017-10-02 2023-04-12 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof
CN111511737B (zh) * 2018-01-29 2022-10-18 南京明德新药研发有限公司 用于治疗细菌感染的单环β-内酰胺化合物
US20220002288A1 (en) * 2018-11-13 2022-01-06 Nanjing Sanhome Pharmaceutical Co., Ltd. Monobactam compounds and use therefor
WO2020125670A1 (zh) 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
EP4079305B1 (en) 2019-12-19 2026-02-18 Shenzhen Optimum Biological Technology Co., Ltd Compounds for use in the treatment of pneumonia caused by certain carbapenem-resistant or carbapenem-susceptible bacteria
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺化合物及其制备方法和应用
CN115210231B (zh) * 2020-07-16 2024-10-08 宁夏农林科学院 单环内酰胺类化合物、其制备方法及其作为抗菌药的用途
EP4007759A4 (en) * 2020-08-06 2024-04-10 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAM COMPOUNDS, THEIR PRODUCTION AND USE AS ANTIBACTERIAL AGENTS
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
WO2023082055A1 (zh) * 2021-11-09 2023-05-19 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
JP2024540478A (ja) * 2021-11-18 2024-10-31 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
CN118255695B (zh) * 2024-02-26 2025-03-14 广州艾奇西医药科技有限公司 一种β-内酰胺类化合物的中间体的纯化方法和制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
EP0336667A3 (en) 1988-04-04 1991-04-10 E.R. Squibb & Sons, Inc. [3S(Z)]-3-[[(2-amino-4-thiazolyl)[[2-(hydroxyamino)-2-oxoethoxy]imino]acetyl]-amino]-2,2-dimethyl-4-oxo-1-azetidinyl sulfate
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (en) 1989-09-21 1991-03-22 Peter H. Ermann Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
AU2002212614B2 (en) 2000-09-14 2006-12-07 Basilea Pharmaceutica Ag 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
US7622502B2 (en) 2004-01-27 2009-11-24 Merck Frosst Canada & Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
ES2374307T3 (es) 2005-09-23 2012-02-15 M's Science Corporation Derivados de piperidina y de piperazina.
DK1965798T3 (da) 2005-12-07 2011-11-28 Basilea Pharmaceutica Ag Nyttige monobactam-antibiotika
WO2007094225A1 (ja) 2006-02-14 2007-08-23 Ihara Chemical Industry Co., Ltd. 5-アルコキシ-4-ヒドロキシメチルピラゾール化合物の製造方法
EP1994035A1 (en) 2006-03-16 2008-11-26 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
JP2010521517A (ja) 2007-03-23 2010-06-24 バジリア ファルマスーチカ アーゲー 細菌感染症を処置するための組合せ薬
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
CA2744756C (en) 2008-12-19 2013-05-28 Pfizer Inc. Monocarbams and their use as antibacterial agent

Also Published As

Publication number Publication date
SG11201403930XA (en) 2014-08-28
EA201400838A1 (ru) 2014-12-30
CY1117955T1 (el) 2017-05-17
NZ626951A (en) 2016-03-31
JP5869701B2 (ja) 2016-02-24
KR20140114390A (ko) 2014-09-26
DK2806873T3 (en) 2016-08-29
TWI659953B (zh) 2019-05-21
HK1203389A1 (zh) 2015-10-30
MX346602B (es) 2017-03-24
MA35905B1 (fr) 2014-12-01
US9556165B2 (en) 2017-01-31
IL233805A (en) 2016-06-30
JP2015504907A (ja) 2015-02-16
SI2806873T1 (sl) 2016-10-28
PL2806873T3 (pl) 2016-12-30
PE20142345A1 (es) 2015-01-09
CL2014001956A1 (es) 2014-11-07
CN104203237A (zh) 2014-12-10
RS55210B1 (sr) 2017-01-31
MY173843A (en) 2020-02-24
BR112014017968A8 (pt) 2017-07-11
AR089796A1 (es) 2014-09-17
KR102036393B1 (ko) 2019-10-24
CA2862338C (en) 2019-04-16
TN2014000297A1 (en) 2015-12-21
MX2014008915A (es) 2014-08-26
IN2014MN01640A (enExample) 2015-05-22
PT2806873T (pt) 2016-09-23
CA2862338A1 (en) 2013-08-01
AU2013211575A1 (en) 2014-07-24
TW201343643A (zh) 2013-11-01
ZA201405057B (en) 2017-09-27
WO2013110643A1 (en) 2013-08-01
CU24273B1 (es) 2017-08-08
IL233805A0 (en) 2014-09-30
BR112014017968A2 (enExample) 2017-06-20
LT2806873T (lt) 2016-10-10
ME02532B (me) 2017-02-20
PH12014501671A1 (en) 2014-11-10
CU20140090A7 (es) 2014-12-26
PH12014501671B1 (en) 2020-02-28
EA027126B1 (ru) 2017-06-30
UY34585A (es) 2013-09-02
US9782390B2 (en) 2017-10-10
EP2806873A1 (en) 2014-12-03
CO7101240A2 (es) 2014-10-31
HUE030452T2 (en) 2017-05-29
AU2013211575B2 (en) 2017-03-02
UA110880C2 (uk) 2016-02-25
EP2806873B1 (en) 2016-06-15
SMT201600354B (it) 2016-11-10
AP2014007880A0 (en) 2014-08-31
HRP20161171T1 (hr) 2016-11-04
ES2592403T3 (es) 2016-11-30
US20150045340A1 (en) 2015-02-12
US20170100379A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
ECSP14010249A (es) Compuestos beta-lactámicos sustituidos con amidina, su preparación y uso como agentes antimicrobianos
CO7101248A2 (es) Compuesos de tetrazolinona y su uso como pesticidas
ECSP14014530A (es) Compuestos inhibidores de metaloenzimas
ECSP14027269A (es) Picolinamidas macrocíclicas como fungicidas
UY35762A (es) Uso de picolinamidas macrocíclicas como fungicidas
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
UY35764A (es) El uso de picolinamidas macrociclicas como fungicidas.
MX2015007379A (es) Nuevos compuestos.
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
EA201201406A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
TR201908180T4 (tr) N1-asil- 5-floropirimidinon deriveleri.
BR112014016635A8 (pt) composto, composição, e, uso de um composto
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
ECSP14011792A (es) Inhibidores de iap
MX369290B (es) Inhibidores de fbx03.
CL2014002868A1 (es) Derivados de azetidina como agentes antiparasitarios; composicion que lo contiene.
DE112013002488T8 (de) Vesikuläre Formulierungen, Kits und Verwendungen